- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03877055
A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma
Phase I/II Clinical Trial of Copanlisib and Ibrutinib in Mantle Cell Lymphoma
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
New Jersey
-
Basking Ridge, New Jersey, United States, 07920
- Memorial Sloan Kettering Basking Ridge
-
Middletown, New Jersey, United States, 07748
- Memorial Sloan Kettering Monmouth
-
-
New York
-
Commack, New York, United States, 11725
- Memorial Sloan Kettering Commack
-
Harrison, New York, United States, 10604
- Memorial Sloan Kettering Westchester
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
Uniondale, New York, United States, 11553
- Memorial Sloan Kettering Nassau
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient is ≥ 18 years of age at the time of signing Informed Consent
- Patient is able and willing to adhere to the study visit schedule and other protocol requirements
Patient has histologically confirmed diagnosis of R/R mantle cell lymphoma who has received at least 1 line of therapy
°Autologous stem cell transplant recipients must have adequate bone marrow recovery and transfusion independent
Patients may have been previously treated with BTK or PI3K inhibitors:
°If BTK/P13K inhibitors were part of their last treatment, patients must have had a best response of stable disease or better
- Patient has at least one measurable lesion (≥ 2 cm) according to RECIL criteria[37]
- Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
Patient has adequate bone marrow and organ function by:
- Absolute neutrophil count (ANC) ≥ 1 x 10^9/L , independent of growth factor support for 14 days unless there is bone marrow involvement. For patients with bone marrow involvement, ANC ≥ 500/uL independent of growth factor support for 14 days
- Platelets ≥100 x 10^9/L, or ≥50 x 10^9/L if bone marrow involvement and independent of transfusion support for 14 days in either situation
- Hemoglobin (Hgb) ≥ 9.0 g/dL (no RBC transfusion within past 14 days)
- International Normalized Ratio (INR) ≤ 1.5
- Serum Creatinine ≤ 1.5 x upper limit of normal (ULN) or creatinine clearance ≥ 25 mL/min as determined by the Cockcroft-Gault equation or a 24 hour urine collection
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ ULN (or ≤ 3 x ULN if liver involved with disease
- Total serum bilirubin ≤ ULN (or ≤ 1.5 x ULN if documented hepatic involvement; or total bilirubin ≤ 3 x ULN with direct bilirubin ≤ 1.5 x ULN in patients with documented Gilbert's Syndrome.
- Lipase ≤ 1.5x ULN
- LVEF ≥ 50%
- Hemoglobin A1c ≤ 8.5%
Exclusion Criteria:
- Patient has a history of non-compliance to medical regimen or inability to grant consent
Patient is concurrently using other approved or investigational antineoplastic agent with the exception of BTK or Pi3K inhibitors in patients who had these agents as the last line of treatment
°Patient on BTK or P13K inhibitors will be continued on therapy as they transition to protocol therapy
- Patient has not recovered to Grade 1 or better (except alopecia) from related side effects of any prior antineoplastic therapy
- Patient has had major surgery or a wound that has not fully healed within 4 weeks of starting study drugs.
- Patients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier.
- Patients who have undergone an allogenic hematopoietic stem cell transplant
- Patient has active or history of central nervous system (CNS) disease or meningeal involvement.
- Patient has history of clinically significant interstitial lung disease and/or lung disease that severely impairs lung function (as judged by the investigator)
- Patient has history of stroke or intracranial hemorrhage ≤ 6 months from starting study drugs.
- Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
- Patient has clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification, Left Ventricular Ejection Fraction (LVEF) <50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO), unstable angina pectoris, symptomatic pericarditis, QTcF > 480 msec on the screening ECG (using the QTcF formula)
- Patient has a concurrent active malignancy. Malignancies treated with a curative intent with an expected life expectancy ≥ 5 years or a non-competing life expectancy risk are eligible (i.e. adequately treated basal or squamous cell carcinoma, non-melanomatous skin cancer, early stage breast cancer, treated prostate cancer or any other cancer from which the patient has been disease free for ≥ 3 years).
- Patient with known history of human immunodeficiency virus (HIV), or any uncontrolled active systemic infection.
- Patient has CMV viremia (peripheral blood CMV PCR positive), acute viral hepatitis (typically defined by elevated AST/ALT), or a history of chronic or active HBV or HCV infection. HBV infection is defined as having HBsAg and/or HBcAb positive test with concurrent detectable HBV DNA levels. HCV infection is defined as detectable HCV RNA levels.
- Patient requires treatment with a strong or moderate cytochrome P450 (CYP) 3A4 inhibitors, and inducers, and the treatment cannot be discontinued or switched to a different medication prior to starting study drug. Moderate and strong CYP modulators (inducers and inhibitors) should have a washout period of at least 5-6 half-lives before initiating ibrutinib or copanlisib.
- Patients with known bleeding diathesis (e.g. von Willebrand 's disease) or hemophilia
- Patient is currently receiving warfarin or other Vitamin K antagonist. Therapy with heparin, low molecular weight heparin (LMWH), or fondaparinux is allowed. Refer to Section 9.5 for Concomitant medication
- Patients with Child Pugh Class B or C hepatic cirrhosis
- Patients with any life threatening illness, medical condition or organ system dysfunction that in the opinion of the investigator could compromise the subject's safety, interfere with absorption of metabolism of study drugs or put the study outcomes at undue risk.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Copanlisib and Ibrutinib
Copanlisib is given intravenously on days 1, 8, and 15 of 28 day cycles.
Ibrutinib is given orally every day on 28 days cycles.
The maximum duration of treatment is 36 cycles not exceeding 36 months.
In the phase II study, the cohort will expand and accrue patients at the recommended phase II dose of copanlisib and ibrutinib determined during phase I dose escalation.
In a simon two stage mini-max design, an initial 18 patients will be enrolled, inclusive of 6 patients treated at MTD or RP2D from phase I study, in first stage.
|
Treatment will be with intravenous copanlisib on days 1, 8, 15 of 28 day cycles.
Oral ibrutinib daily in 28 day cycles.
A cycle is defined as 28 days of therapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete Response
Time Frame: 2 years
|
using the RECIL criteria
|
2 years
|
Collaborators and Investigators
Collaborators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18-450
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Supporting Information Type
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mantle Cell Lymphoma (MCL)
-
BeiGeneRecruitingMantle Cell Lymphoma | Relapsed Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma (MCL)United States, China, Israel, Belgium, Poland, Spain, Turkey, Brazil, Italy, Canada, United Kingdom, France, Germany, Argentina, Puerto Rico
-
AbbVieActive, not recruiting
-
Acerta Pharma BVActive, not recruitingMantle Cell Lymphoma (MCL)Belgium, France, United Kingdom, United States, Italy, Poland, Netherlands, Australia, Czechia, Spain
-
AstraZenecaRecruitingMantle Cell Lymphoma (MCL)Canada, Poland, United Kingdom, United States, Brazil, Spain, Australia
-
Peking University Third HospitalPeking University First Hospital; Shanxi Province Cancer Hospital; 307 Hospital... and other collaboratorsRecruitingMantle Cell Lymphoma (MCL)China
-
Acerta Pharma BVAstraZenecaActive, not recruitingMantle Cell Lymphoma (MCL)United States, Poland, Italy
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownRelapsed / Refractory Mantle Cell Lymphoma (MCL)China
-
US Oncology ResearchEli Lilly and CompanyCompletedRelapsed or Refractory Mantle Cell Lymphoma (MCL)
-
Guangzhou Lupeng Pharmaceutical Company LTD.RecruitingMantle Cell Lymphoma (MCL)China
-
Nordic Lymphoma GroupAstraZenecaActive, not recruitingMantle Cell Lymphoma | MCLFinland, Sweden, Norway, Denmark, Korea, Republic of
Clinical Trials on Copanlisib
-
Dorothy Sipkins, MD, PhDBayerTerminatedLeukemia, Acute LymphocyticUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingRefractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)United States
-
BayerTerminatedOsteosarcoma | Ewing Sarcoma | Neuroblastoma | Rhabdomyosarcoma | Relapsed or Refractory Solid Tumors or Lymphoma in ChildrenUnited States
-
BayerCompleted
-
BayerActive, not recruitingRelapsed or Refractory Indolent Non-Hodgkin LymphomaTaiwan
-
BayerCompleted
-
BayerNo longer availableCancerBrazil, Hong Kong, Hungary, Malaysia, Poland, Romania, Russian Federation, Taiwan, Ukraine, Ireland, Chile
-
BayerCompletedHepatic Insufficiency, Renal InsufficiencyGermany, Romania
-
Columbia UniversityBayerActive, not recruiting